Increased risk of diabetes mellitus and hyperlipidemia in patients with differentiated thyroid cancer
Main finding · Composite CMDResult — go to the resultHazard ratio 1.11 95% CI 1.04–1.19Authors' conclusion
Patients with DTC had an increased risk of CMD, especially DM and hyperlipidemia, but a low risk of CMD mortality. Special attention to metabolic diseases is required in the long-term follow-up of patients with DTC.
Study context
- Population
- Patients with differentiated thyroid cancer (DTC) and matched controls, population-based nationwide cohort in Koreamatched cohort
- Participants
- 2,649 vs 7,947
- Exposure
- DTC vs matched controls
- DTCn = 2,649
- Controlsn = 7,947reference
- Outcome
- Composite of cardiometabolic disease (CMD):
- DM
- Hypertension
- Hyperlipidemia
- Cerebrovascular disease
- Ischemic heart disease
Methodological detailsnationwide, matched controls
- Nationwide
- Matched controls
Main finding
Composite CMD
Hazard ratio
1.11
95% CI 1.04–1.19
DTCvs Controls
HR 1.11 (95% CI 1.04–1.19)
As reported in the abstract
Observational data: associations, not effects.
Secondary outcomes
| Outcome | HR (95% CI) | |
|---|---|---|
| DM | 1.22 (1.08–1.38) | |
| Hyperlipidemia | 1.36 (1.24–1.48) | |
| CMD-specific mortality | 0.24 (0.09–0.68) | |
| 0.050.21520Hazard ratio (log scale) |
Daily levothyroxine dose and diabetes mellitus (DM) / hyperlipidemia risk in DTC
- Nonlinear, U-shaped relationship between daily LT4 dose and DM risk
- P = 0.021
- Low hyperlipidemia risk with high LT4 doses
- P = 0.003
Original publication
Increased risk of diabetes mellitus and hyperlipidemia in patients with differentiated thyroid cancer. Eur J Endocrinol. Published 27 March 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →